Fig 1: Bar plot of TIICs in PRCC and comparison of TIICs in PRCC1 and PRCC2 (A-B). Survival curves of M1 and M2 macrophage in sPRCC2 (C-D). Correlation heat map of various TIICs (E). Correlation analysis of TPX2 and various immune regulatory genes including IDO1, MICB, TNFRSF9, CXCL13 (F-I)
Fig 2: Volcano map of DEGs between high and low TPX2 expression groups (A). PPI network of the DEGs (B). GO and KEGG functional enrichment analysis of DEGs (C-D). Expression level of KIFs in low and high risk groups (E)
Fig 3: HE staining and FH staining of PRCC2 (A, B). Representative images of low and high TPX2 expression in sPRCC2 (C, D). Overall survival curve and progression-free survival of TPX2 expression in FUSCC cohort (E–F). Progression-free survival curve of sPRCC2 patients treated with Everolimus in FUSCC cohort (G). Progression-free survival curve of high risk sPRCC2 patients treated with Sunitinib or Everolimus (H). Tumor reduction image of sPRCC2 patients in FUSCC cohort
Fig 4: PPI network and hub genes of common down-regulated genes (A-B). PPI network and hub genes of common up-regulated genes (C-D). Overall survival curve of low and high TPX2 expression group in sPRCC2 (E). Clinical stage, T stage and lymph node stage of two groups (F–H)
Supplier Page from Abcam for Anti-TPX2 antibody [EPR23180-4] - BSA and Azide free